Takeda Pharmaceutical Co. Ltd. has completed its acquisition of Nycomed A/S for 9.6 billion Euro, making Nycomed a wholly owned subsidiary of Takeda. Dr. Frank Morich has been named chief executive officer of Nycomed in addition to his current role as executive vice president, International Operations (Americas/Europe). The transaction is part of Takeda’s growth strategy. Nycomed adds significant business infrastructure in Europe and emerging markets, enhancing Takeda’s regulatory d...